Linagliptin (BI-1356) is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM and exhibits a 10,000-fold higher selectivity for DPP-4 than for other dipeptidyl peptidases such as DPP-2, DPP-8, and DPP-9. Linagliptin activates glomerular autophagy in a model of type 2 diabetes. DPP4 mediates ferroptosis in TP53-deficient CRC cells.
Ferroptosis Inhibitors Related Products:
SB-202190; Rosiglitazone; Bardoxolone methyl; Curcumin; Troglitazone; Setanaxib; Imidazole ketone erastin